logo
logo
AMRN stock ticker logo

Amarin Corporation plc

NASDAQ•AMRN
CEO: Mr. Aaron D. Berg
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1993-04-01
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Contact Information
Iconic Offices, The Greenway, Block C Ardilaun Court St Stephens Green, Dublin, 112-114, Ireland
353-0-166-99020
www.amarincorp.com
Market Cap
$315.21M
P/E (TTM)
-9.4
24.5
Dividend Yield
--
52W High
$20.90
52W Low
$12.30
52W Range
34%
Rank57Top 83.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Deep Research

Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data